Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD3-CD20 bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Benhealth Biopharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Rectal, Vaginal, Intradermal, Intravitreal, Intratumoral, Intralesional, Intraperitoneal, Intra-arterial, Percutaneous, Parenteral, Implant
01
Overview
The CD3-CD20 bispecific antibody is a preclinical-stage T-cell engaging therapeutic being developed by Benhealth Biopharmaceutical. Engineered using the company's proprietary ExMab platform, the antibody is designed to bridge T-cells and B-cells by simultaneously targeting the CD3 epsilon subunit of the T-cell receptor complex and the CD20 antigen expressed on the surface of B-lymphocytes. This mechanism of action triggers the formation of an immunological synapse, leading to the activation and proliferation of cytotoxic T-cells and the subsequent directed lysis of CD20-positive cells. The program is intended for the treatment of various B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia, where CD20 is a well-validated therapeutic target.
- Other names
- CD3/CD20 bispecific antibodyanti-CD3 x anti-CD20 bispecific antibodyanti-CD-3 x anti-CD20 bispecific antibodyanti-CD 3 x anti-CD20 bispecific antibody
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CD3-CD20 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD3-CD20 bispecific antibody.